Medical University of Graz
Graz, Austria
NCT Number: NCT04136587
Secreted bacterial effectors produced by the intestinal microbiota are in part responsible for the proinflammatory effect of the fecal content in inflammatory bowel disease (IBD) patients.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Graz, Austria
Fecal colonic content will be collected by suction during routine colonoscopy. From the fecal content different fractions (containing soluble bacterial fractions and membrane bound bacterial fractions) will be processed. These bacterial fractions (also termed as bacterial secretome) will be tested for proinflammatory potential in tissue culture assays including epithelial colonic cell lines and dendritic/monocytic cell lines. The main outcome parameter will be the secretion of proinflammatory cytokines from the tissue culture.
For this purpose the investigators will test different groups of patients including patients with active/inactive Crohn's disease or ulcerative colitis, patients with other inflammatory conditions of the colon, patients with colorectal carcinoma and healthy controls undergoing colonoscopy.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Group 1 (healthy controls): n=20
Inclusion criteria
Exclusion criteria
Group 2 (Crohn´s disease; CD): n= 20 (10 active CD; 10 inactive CD)
Inclusion criteria
Exclusion criteria
Definition of active CD Harvey-Bradshaw Index - HBI ≥ 5 and / or Simple Endoscopic Score for Crohn Disease (SES-CD) ≥ 3
Except SES-CD scores resulting from isolated lesions only located at the ileocolonic anastomosis consistent with a modified Rutgeerts score i2a (these patients are considered as endoscopically non active)
Definition of inactive CD
Harvey-Bradshaw Index (HBI) < 5 and Simple Endoscopic Score for Crohn Disease (SES-CD) < 3
Except SES-CD scores resulting from isolated lesions only located at the ileocolonic anastomosis consistent with a modified Rutgeerts score i2a (these patients are considered as endoscopically non active)
Group 3 (Ulcerative colitis, UC): n= 20 (10 active UC; 10 inactive UC)
Inclusion criteria
Exclusion criteria
Definition of active UC Total Mayo score ≥ 3 and Endoscopic Mayo subscore ≥ 2
Definition of inactive UC Total Mayo score < 3 and Endoscopic Mayo subscore 0 or 1.
Group 4 (Colorectal cancer): n= 10
Inclusion criteria
Exclusion criteria
Group 5 (Colitis/Enteritis of different origin): n= 20
Inclusion criteria
Exclusion criteria
Colonic content will be collected by suction during routine colonoscopy including the residual fluid in the colon and stool contents and also suction of washing fluid (sterile physiologic H2O solution)
Time frame: One day
Measurement of proinflammatory cytokines (f.e.: IL-8) in epithelial and dendritic tissue culture assays
Time frame: One day
Measurement of proinflammatory cytokines (f.e.: IL-8) in epithelial and dendritic tissue culture assays
Time frame: one day
Measurement of proinflammatory cytokines (f.e.: IL-8) in epithelial and dendritic tissue culture assays
Time frame: One day
Measurement of proinflammatory cytokines (f.e.: IL-8) in epithelial and dendritic tissue culture assays
Medical University of Graz
Other
The Bacterial Secretome in Crohn's Disease and Ulcerative Colitis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04757181
Digestive System Diseases, Gastroenteritis
Worcester, Massachusetts, United States
View Trial DetailsNCT03938324
Anemia, Anemia, Hemolytic
Durham, North Carolina, United States
View Trial DetailsNCT06094608
Colitis, Colitis, Ulcerative
Ann Arbor, Michigan, United States
View Trial DetailsNCT05809999
Colonic Diseases, Colonic Neoplasms
Edmonton, Alberta, Canada
View Trial Details